[1] Harpaz R, Dumochel W, Shah NH.Big data and adverse drug reaction detection[J]. Clin Pharmacol Ther, 2016,99(3):268-270. [2] Duggirala H J, Tonning JM, Smith E, et al.Use of data mining at the Food and Drug Administration[J]. J Am Med Inform Assoc,2016,23(2):428-434. [3] Vilar S, Friedman C, Hripcsak G.Detection of drug-drug interactions through data mining studies using clinical sources,scientific literature and social media[J]. Briefings in bioinformatics,2017, 19(5): 863-877. [4] World Health Organization.Pharmacovigilance: ensuring the safe use of medicines[R]. Geneva: World Health Organization,2004. [5] Bourgeois FT, Orenstein L, Ballakur S,et al.Exclusion of Elderly People from Randomized Clinical Trials of Drugs for Ischemic Heart Disease[J]. Journal of the American Geriatrics Society,2017, 65(11): 2354-2361. [6] Zoccali C, Blankestijn PJ, Bruchfeld A, et al.Children of a Lesser God: Exclusion of Chronic Kidney Disease Patients from Clinical Trials[J]. Nephrology Dialysis Transplantation, 2019, 34(7):1112-1114. [7] Lockett J, Sauma S, Radziszewska B, et al.Adequacy of inclusion of older adults in NIH‐funded phase III clinical trials[J].Journal of the American Geriatrics Society, 2019, 67(2): 218-222. [8] Zoccali C, Blankestijn PJ, Bruchfeld A, et al.Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials[J]. Nephrology Dialysis Transplantation, 2019,34(7): 1112-1114. [9] Ristevski B, Chen M.Big data analytics in medicine and healthcare[J]. Journal of integrative bioinformatics, 2018, 15(3):1-5. [10] Sherman RE, Anderson SA, Dal Pan GJ, et al.Real-world evidence-what is it and what can it tell us?[J].N Engl J Med,2016,375(23):2293-2297. [11] Woodcock J.Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs?[J].Clin Pharmacol Ther,2012, 91(3):378-380. [12] Hripcsak G, Albers DJ.Next-generation phenotyping of electronic health records[J]. Journal of the American Medical Informatics Association, 2012, 20(1): 117-121. [13] Wagholikar KB, Sundararajan V, Deshpande AW.Modeling paradigms for medical diagnostic decision support: a survey and future directions[J]. Journal of medical systems, 2012, 36(5):3029-3049. [14] Sullivan P, Goldmann D.The promise of comparative effectiveness research[J]. Jama, 2011, 305(4): 400-401. [15] Bate A, Juniper J, Lawton AM,et al.Designing and incorporating a real world data approach to international drug development and use: what the UK offers[J]. Drug Discov Today, 2016,21(3):400-405. [16] Moore TJ, Furberg CD.Electronic health data for post-market surveillance: a vision not realized[J]. Drug Saf, 2015,38(7):601-610. [17] Bate A, Pariente A, Hauben M, et al.Quantitative signal detection and analysis in pharmacovigilance[J]. Mann's pharmacovigilance,2014: 331-354. [18] Uppsala Monitoring Centre. Vigibase webpage[EB/OL].(2017-07-25)[2019-09-30].https://www. who-umc.org/vigibase/vigibase/. [19] Food and Drug Administration (FDA). Reports received and reports entered into FAERS by year[EB/OL].(2017-07-25)[2019-09-30].https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/reports-received-and-reports-entered-faers-year. |